Various viruses engineered to express IL-7 have now been tested in several preclinical cancer models [27–29], demonstrating superior antitumor immunity via activation of TILs—a hallmark of “immunologically hot” tumors [67]—compared to non-IL7-expressing viruses. This evidence concerns the gene IL7 and cancer.